Jump Financial’s Recursion Pharmaceuticals RXRX Stock Holding History

Jump Financial’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.74M	Buy	1,019,173 +129,240	+15%	+$430K	0.03%	623
2026 Q1	$2.73M	Buy	889,933 +228,304	+35%	+$882K	0.04%	546
2025 Q4	$2.71M	Buy	661,629 +106,551	+19%	+$528K	0.03%	569
2025 Q3	$2.71M	Sell	555,078 -596,123	-52%	-$3.13M	0.03%	621
2025 Q2	$5.83M	Buy	1,151,201 +558,848	+94%	+$2.75M	0.06%	372
2025 Q1	$3.13M	Buy	592,353 +578,859	+4,290%	+$4.22M	0.04%	451
2024 Q4	$91.2K	Buy	+13,494	New	+$90.7K	﹤0.01%	1548
2023 Q4	–	Sell	-253,464	Closed	-$1.94M	–	2182
2023 Q3	$1.94M	Buy	253,464 +241,615	+2,039%	+$2.41M	0.07%	383
2023 Q2	$88.5K	Sell	11,849 -117,692	-91%	-$823K	﹤0.01%	1671
2023 Q1	$864K	Buy	+129,541	New	+$1.03M	0.04%	659

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jump Financial's RXRX Position: Q2 2026 in Review

Jump Financial increased its Recursion Pharmaceuticals (RXRX) stake by 15% in Q2 2026, buying an estimated $430K and bringing the position to 1,019,173 shares worth $3.74M. The position accounts for 0.03% of the portfolio, ranked #623.

Jump Financial first reported a position in RXRX in Q1 2023 and has held it in 10 quarters since. The position peaked at $5.83M in Q2 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Jump Financial held 1,019,173 shares of Recursion Pharmaceuticals worth $3.74M as of Q2 2026.
Jump Financial bought 129,240 Recursion Pharmaceuticals shares in Q2 2026, an estimated $430K.
Recursion Pharmaceuticals made up 0.03% of Jump Financial's portfolio in Q2 2026, its #623 holding.
Jump Financial first reported a position in Recursion Pharmaceuticals in Q1 2023 and has held it in 10 quarters since.
Jump Financial's Recursion Pharmaceuticals position peaked at $5.83M in Q2 2025.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.